A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection

J Infect Dis. 2011 Feb 15;203(4):473-8. doi: 10.1093/infdis/jiq077. Epub 2011 Jan 13.

Abstract

A double-blinded, controlled study of vaccination of untreated patients with chronic human immunodeficiency virus type 1 (HIV-1) infection with 3 doses of autologous monocyte-derived dendritic cells (MD-DCs) pulsed with heat inactivated autologous HIV-1 was performed. Therapeutic vaccinations were feasible, safe, and well tolerated. At week 24 after first vaccination (primary end point), a modest significant decrease in plasma viral load was observed in vaccine recipients, compared with control subjects (P = .03). In addition, the change in plasma viral load after vaccination tended to be inversely associated with the increase in HIV-specific T cell responses in vaccinated patients but tended to be directly correlated with HIV-specific T cell responses in control subjects.

Trial registration: ClinicalTrials.gov NCT00402142.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / administration & dosage*
  • AIDS Vaccines / adverse effects
  • Adult
  • Dendritic Cells / immunology*
  • Double-Blind Method
  • Female
  • HIV Infections / immunology
  • HIV Infections / therapy*
  • HIV Infections / virology
  • HIV-1 / immunology*
  • HIV-1 / isolation & purification
  • Humans
  • Immunotherapy / adverse effects
  • Immunotherapy / methods*
  • Male
  • Middle Aged
  • RNA, Viral / blood
  • T-Lymphocytes / immunology
  • Treatment Outcome
  • Viral Load

Substances

  • AIDS Vaccines
  • RNA, Viral

Associated data

  • ClinicalTrials.gov/NCT00402142